Subject(s)
Humans , Male , Female , Allergens , Antineoplastic Agents/adverse effects , Biological Factors/adverse effects , Drug Hypersensitivity/diagnosis , Desensitization, Immunologic/methods , Retrospective Studies , Pilot Projects , Carboplatin/adverse effects , Oxaliplatin/adverse effects , Skin Tests , Taxoids/adverse effectsSubject(s)
Allergens/adverse effects , Antineoplastic Agents/adverse effects , Biological Factors/therapeutic use , Drug Hypersensitivity/diagnosis , Immunization/methods , Antineoplastic Agents/therapeutic use , Biological Factors/adverse effects , Carboplatin/adverse effects , Carboplatin/therapeutic use , Female , Humans , Male , Oxaliplatin/adverse effects , Oxaliplatin/therapeutic use , Pilot Projects , Skin Tests , Taxoids/adverse effects , Taxoids/therapeutic useABSTRACT
The disease caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ie, coronavirus disease 2019 (COVID-19), has become a global pandemic since it was first reported in Wuhan, China in December 2019. Its severe clinical manifestations, which often necessitate admission to intensive care units, and high mortality rate represent a therapeutic challenge for the medical community. To date, no drugs have been approved for its treatment, and various therapeutic options are being assayed to address the pathophysiological processes underlying the clinical manifestations experienced by patients. New and old drugs administered as monotherapy or in combination to immunologically compromised patients may favor the development of adverse drug reactions, including drug hypersensitivity reactions, which must be identified and managed accordingly. Given the lack of herd immunity and the high rate of viral contagion, new cases are expected to emerge in the coming months. Thus, the probability of more adverse reactions or even new clinical manifestations may increase in parallel. Allergists must receive updated information on these treatments, as well as on the management of possible drug hypersensitivity reactions.
Subject(s)
COVID-19 Drug Treatment , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/etiology , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , COVID-19/complications , COVID-19/immunology , COVID-19/pathology , Cytokines/antagonists & inhibitors , Diagnosis, Differential , Humans , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Delayed/etiology , Hypersensitivity, Immediate/diagnosis , Hypersensitivity, Immediate/etiology , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , SARS-CoV-2ABSTRACT
The disease caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ie, coronavirus disease 2019 (COVID-19), has become a global pandemic since it was first reported in Wuhan, China in December 2019. Its severe clinical manifestations, which often necessitate admission to intensive care units, and high mortality rate represent a therapeutic challenge for the medical community. To date, no drugs have been approved for its treatment, and various therapeutic options are being assayed to address the pathophysiological processes underlying the clinical manifestations experienced by patients. New and old drugs administered as monotherapy or in combination to immunologically compromised patients may favor the development of adverse drug reactions, including drug hypersensitivity reactions, which must be identified and managed accordingly. Given the lack of herd immunity and the high rate of viral contagion, new cases are expected to emerge in the coming months. Thus, the probability of more adverse reactions or even new clinical manifestations may increase in parallel. Allergists must receive updated information on these treatments, as well as on the management of possible drug hypersensitivity reactions
La enfermedad causada por el nuevo Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), se ha expandido en forma de pandemia global desde su inicio en Wuhan (China) en diciembre de 2019. La aparición de formas clínicas graves asociadas a la necesidad de ingreso en unidades de Cuidados Intensivos, con un alto índice de letalidad, ha supuesto un reto terapéutico para la comunidad médica. Actualmente no hay ningún fármaco aprobado para su tratamiento y se están ensayando diversas opciones terapéuticas para abordar los procesos fisiopatológicos responsables de las manifestaciones clínicas que experimentan los pacientes. Tanto el uso de viejos como de nuevos principios activos como tratamiento único o en combinación, en pacientes inmunológicamente comprometidos, puede favorecer la aparición de efectos adversos, entre ellos reacciones de hipersensibilidad de mecanismo inmunológico, que habrá que saber identificar y manejar correctamente. Es de prever que, en los próximos meses, dada la falta de inmunidad comunitaria y el elevado índice de contagiosidad del virus, sigan surgiendo nuevos casos y, con ello, la probabilidad de que aparezcan más reacciones adversas o incluso nuevas manifestaciones clínicas. Es importante que los alergólogos estén al día de las opciones terapéuticas que se están utilizando, así como de sus posibles reacciones adversas, inclusive reacciones de hipersensibilidad y cómo manejarlas
Subject(s)
Humans , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Pandemics , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Drug HypersensitivityABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Bee Venoms/adverse effects , Multiple Organ Failure/etiology , Anaphylaxis/physiopathology , Anaphylaxis/complications , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Arthropod Venoms/adverse effects , Anaphylaxis/immunology , Dermatitis, Atopic/immunology , Hymenoptera , Cloning, Molecular , Retrospective Studies , Cross-Sectional Studies , Stem Cells/immunologyABSTRACT
No disponible